A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6300 participants.

Also called NCT01958957

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 6,300 participants (enrolled count) (from the registry)
Sponsor
Jiangsu Kanion Pharmaceutical Co., Ltd (from the registry)
Registry
  • NCT NCT01958957
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01958957. Allocation not applicable; no masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.
Intervention (Drug)
Ginkgolides Meglumine Injection
Lead sponsor
Jiangsu Kanion Pharmaceutical Co., Ltd (class: industry)
Collaborator
Beijing Bionovo Medicine Development Co., Ltd. (class: other)

Record details

Record id
cardio:ct-nct01958957
Content hash
338e0e9aa3db2437d80787f3f5be67d67964e4d5d7937871b64a5d75617b206f